Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (BCRX) announced the grant of stock options and restricted stock units (RSUs) to 17 new employees, totaling 290,000 shares. The options have an exercise price of $16.61, aligned with the closing stock price on February 28, 2022. These grants aim to attract talent as part of Nasdaq Listing Rule 5635(c)(4). The options and RSUs will vest over four years, contingent on continued employment. BioCryst specializes in oral treatments for rare diseases and continues to advance its product pipeline including ORLADEYO and BCX9930.

BioCryst Pharmaceuticals (BCRX) announced promising long-term efficacy and safety results from the APeX-2 trial of ORLADEYO (berotralstat), aimed at treating hereditary angioedema (HAE). Data presented at the 2022 AAAAI annual meeting revealed that patients had a remarkable average of 94 percent attack-free days over 96 weeks. The study involved 121 patients, showing sustained attack rate reductions across various groups. ORLADEYO was well-tolerated, with no serious adverse events, suggesting its potential as an effective prophylactic therapy.

BioCryst Pharmaceuticals reported Q4 2021 revenues of $47.2 million, driven largely by $46.2 million from ORLADEYO, marking a significant increase from $4 million in Q4 2020. For FY 2021, total revenues reached $157.2 million, with ORLADEYO contributing $122.6 million. The company anticipates 2022 ORLADEYO revenues of no less than $250 million. With over $500 million in cash, BioCryst plans to expand its pipeline, focusing on the advancements in its Factor D programs for rare diseases.

BioCryst Pharmaceuticals (BCRX) has enrolled its first patient in the RENEW study, aimed at assessing the oral Factor D inhibitor, BCX9930, in renal diseases such as C3 glomerulopathy, IgAN, and PMN. This multicenter trial will involve about 42 patients receiving BCX9930 over 24 weeks, with the primary endpoint being the change in urine protein-to-creatinine ratio. The company is also advancing its clinical efforts with BCX9930 in ongoing REDEEM trials for PNH, seeking to establish regulatory approvals over the next two years.

BioCryst Pharmaceuticals, Inc. (BCRX) plans to release its fourth quarter and full year 2021 financial results on February 23, 2022. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the call via telephone or online, with a replay available afterward. BioCryst specializes in discovering novel oral medicines for rare diseases, with products like ORLADEYO and ongoing development programs targeting complement-mediated diseases and viral infections.

BioCryst Pharmaceuticals has appointed Machelle Sanders, North Carolina Secretary of Commerce and a veteran in pharmaceutical operations, to its board of directors. With over 30 years of experience, including leadership roles at Biogen, Sanders brings extensive expertise in scaling operations while maintaining quality control. Her appointment comes as BioCryst builds on the success of ORLADEYO, its recently launched oral treatment for rare diseases. Sanders emphasized the potential for growth through effective commercialization and innovation in R&D.

BioCryst Pharmaceuticals (BCRX) announced the grant of stock options and restricted stock units (RSUs) to 31 newly-hired employees, totaling 213,500 shares in options and 24,700 shares in RSUs. The options have an exercise price of $15.45 per share, equal to the stock's closing price on January 31, 2022. Vesting occurs in four equal annual installments, starting one year after the grant date, contingent upon continued employment. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent within the company.

BioCryst Pharmaceuticals (BCRX) announces the presentation of three abstracts on ORLADEYO® (berotralstat) at the 2022 AAAAI annual meeting in Phoenix, AZ, from February 25-28. The data highlights sustained reductions in hereditary angioedema (HAE) attack rates and improved quality of life in patients after 96 weeks of treatment. Dr. William Sheridan emphasized ORLADEYO's value as a once-daily prophylactic option. The abstracts detail the treatment's efficacy and are accessible in an online supplement to The Journal of Allergy and Clinical Immunology.

BioCryst Pharmaceuticals reported preliminary ORLADEYO revenues of $45.6 million for Q4 2021 and $122 million for FY 2021. The company expects revenues to exceed $250 million in 2022 as patient demand remains strong, with a projected peak sales of $1 billion. The enrollment of patients in pivotal trials for BCX9930, an oral Factor D inhibitor, has also commenced. BioCryst aims to increase market share in HAE prophylaxis, with strong retention rates among patients switching from injectable therapies.